Literature DB >> 16396645

Screening compliance and visual outcome in diabetes.

Gunnar Már Zoega1, Thornóra Gunnarsdóttir, Sigríethur Björnsdóttir, Astradur B Hreietharsson, Guethmundur Viggósson, Einar Stefánsson.   

Abstract

PURPOSE: To study the relationship between screening compliance and visual outcome in a screening programme for diabetic eye disease.
METHODS: A retrospective case control study. The screening compliance of all the diabetes patients (n = 22) listed at the Icelandic National Registry for the Blind (visual acuity <0.3) was compared to a matched group of 44 non-blind diabetes patients (visual acuity > or =0.3) who participated in the same screening programme for diabetic retinopathy. Glycaemic control (HbA1c), office blood pressure and cholesterol levels were assessed.
RESULTS: The study group had a significantly lower level of compliance with the screening programme (27% +/- 38% [mean +/- SD] versus 77% +/- 26% [mean +/- SD]; p < 0.0001). Macular oedema or proliferative diabetic retinopathy was found in 60% (13/22) of the study group when entering the screening programme, compared to 7% (3/44) in the control group. Blood pressure (except diastolic BP among type 1 diabetes mellitus), blood glucose and cholesterol levels were identical. The prevalence of blindness and low vision amongst diabetes patients in Iceland is about 0.5%.
CONCLUSIONS: There was a significant relationship between screening compliance and visual outcome in diabetes patients in our screening programme.

Entities:  

Mesh:

Year:  2005        PMID: 16396645     DOI: 10.1111/j.1600-0420.2005.00541.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  24 in total

Review 1.  Screening for diabetic retinopathy and diabetic macular edema in the United Kingdom.

Authors:  Tunde Peto; Christine Tadros
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

2.  Prevention of diabetic blindness.

Authors:  E Stefánsson
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

3.  Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy.

Authors:  T Aspelund; O Thornórisdóttir; E Olafsdottir; A Gudmundsdottir; A B Einarsdóttir; J Mehlsen; S Einarsson; O Pálsson; G Einarsson; T Bek; E Stefánsson
Journal:  Diabetologia       Date:  2011-07-27       Impact factor: 10.122

4.  The effect of geodemographic factors on the attendance rates at a regional diabetic retinopathy treatment centre.

Authors:  Emily Greenan; Marisa Salim; Daniel Nicholas Coakley; Mark James
Journal:  Ir J Med Sci       Date:  2019-04-18       Impact factor: 1.568

5.  Visual impairment and associated risk factors in patients with diabetes mellitus in Tavush and Armavir provinces of Armenia.

Authors:  Aida Giloyan; Diana Muradyan; Vahe Khachadourian
Journal:  Int Ophthalmol       Date:  2021-08-11       Impact factor: 2.031

Review 6.  How the diabetic eye loses vision.

Authors:  Jaime A Davidson; Thomas A Ciulla; Janet B McGill; Keri A Kles; Pamela W Anderson
Journal:  Endocrine       Date:  2007-09-27       Impact factor: 3.633

7.  Biennial eye screening in patients with diabetes without retinopathy: 10-year experience.

Authors:  E Olafsdóttir; E Stefánsson
Journal:  Br J Ophthalmol       Date:  2007-07-12       Impact factor: 4.638

8.  Factors that influence the patient uptake of diabetic retinopathy screening.

Authors:  E Dervan; D Lillis; L Flynn; A Staines; D O'Shea
Journal:  Ir J Med Sci       Date:  2008-07-19       Impact factor: 1.568

9.  Retinal Telemedicine.

Authors:  Ru-Ik Chee; Dana Darwish; Alvaro Fernandez-Vega; Samir Patel; Karyn Jonas; Susan Ostmo; J Peter Campbell; Michael F Chiang; Rv Paul Chan
Journal:  Curr Ophthalmol Rep       Date:  2018-01-29

10.  Sensitivity and specificity of Norwegian optometrists' evaluation of diabetic retinopathy in single-field retinal images - a cross-sectional experimental study.

Authors:  Vibeke Sundling; Pål Gulbrandsen; Jørund Straand
Journal:  BMC Health Serv Res       Date:  2013-01-10       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.